Key Points
- SVP Kerr Holbrook sold 15,000 shares at an average of $11.00 on Nov. 18 for $165,000, reducing his stake by 15.17% to 83,860 shares (≈$922,460).
- Avanos beat Q3 estimates, reporting $0.22 EPS vs. $0.12 expected and $177.8M revenue vs. $164.5M, but the company still posted a -67% net margin and set FY25 guidance of 0.85–0.95 EPS (sell-side forecast 1.32).
- Institutional investors own 95.17% of the stock with several large stake increases, yet analyst sentiment is mixed and the consensus rating is "Reduce".
Avanos Medical, Inc. (NYSE:AVNS - Get Free Report) SVP Kerr Holbrook sold 15,000 shares of the firm's stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $11.00, for a total transaction of $165,000.00. Following the completion of the transaction, the senior vice president directly owned 83,860 shares of the company's stock, valued at approximately $922,460. This represents a 15.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Avanos Medical Stock Performance
AVNS traded down $0.02 on Thursday, reaching $11.22. 17,964 shares of the stock were exchanged, compared to its average volume of 541,341. The company's 50-day moving average price is $11.55 and its 200 day moving average price is $11.85. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.38 and a quick ratio of 1.36. The firm has a market capitalization of $520.60 million, a PE ratio of -1.10 and a beta of 1.19. Avanos Medical, Inc. has a fifty-two week low of $9.30 and a fifty-two week high of $19.91.
Avanos Medical (NYSE:AVNS - Get Free Report) last issued its earnings results on Wednesday, November 5th. The company reported $0.22 EPS for the quarter, beating analysts' consensus estimates of $0.12 by $0.10. Avanos Medical had a positive return on equity of 6.21% and a negative net margin of 67.00%.The firm had revenue of $177.80 million for the quarter, compared to analyst estimates of $164.50 million. During the same quarter in the prior year, the firm earned $0.33 earnings per share. Avanos Medical's revenue for the quarter was up 4.3% on a year-over-year basis. Avanos Medical has set its FY 2025 guidance at 0.850-0.950 EPS. As a group, sell-side analysts forecast that Avanos Medical, Inc. will post 1.32 EPS for the current fiscal year.
Institutional Trading of Avanos Medical
Institutional investors have recently modified their holdings of the stock. Armistice Capital LLC purchased a new position in Avanos Medical in the 1st quarter valued at about $28,660,000. T. Rowe Price Investment Management Inc. boosted its stake in shares of Avanos Medical by 24.8% in the first quarter. T. Rowe Price Investment Management Inc. now owns 3,757,576 shares of the company's stock worth $53,847,000 after acquiring an additional 746,264 shares during the last quarter. Millennium Management LLC increased its position in shares of Avanos Medical by 312.4% during the third quarter. Millennium Management LLC now owns 896,242 shares of the company's stock worth $10,361,000 after purchasing an additional 678,898 shares in the last quarter. Clark Estates Inc. NY acquired a new position in Avanos Medical in the 1st quarter valued at $7,077,000. Finally, Ameriprise Financial Inc. raised its holdings in Avanos Medical by 356.6% in the 3rd quarter. Ameriprise Financial Inc. now owns 591,181 shares of the company's stock valued at $6,834,000 after buying an additional 461,706 shares during the period. Institutional investors and hedge funds own 95.17% of the company's stock.
Analyst Ratings Changes
Several analysts recently commented on the company. Zacks Research raised Avanos Medical to a "hold" rating in a report on Tuesday, August 12th. Wall Street Zen raised shares of Avanos Medical from a "buy" rating to a "strong-buy" rating in a report on Saturday, November 8th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Avanos Medical in a research report on Tuesday, October 14th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Avanos Medical presently has a consensus rating of "Reduce".
Check Out Our Latest Research Report on Avanos Medical
Avanos Medical Company Profile
(
Get Free Report)
Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
